Findings

What do systematic reviews say?

31 questions · 37 findings · 2 reviews · Heart

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 10.8%Low 21 · 56.8%Moderate 9 · 24.3%High 3 · 8.1%

Non‐vitamin‐K‐antagonist oral anticoagulants vs placebo

Apixaban (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation

3 findings from 1 review

Non‐vitamin‐K‐antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta‐analysis 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 8638 participants
Moderate
Non‐vitamin‐K‐antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta‐analysis 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 8638 participants
Moderate
Non‐vitamin‐K‐antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta‐analysis 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 8544 participants
High

Non‐vitamin‐K‐antagonist oral anticoagulants vs placebo

Rivaroxaban (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation

3 findings from 1 review

Non‐vitamin‐K‐antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta‐analysis 2024 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 21870 participants
High
Non‐vitamin‐K‐antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta‐analysis 2024 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 21870 participants
Moderate
Non‐vitamin‐K‐antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta‐analysis 2024 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 21870 participants
High

Non‐vitamin‐K‐antagonist oral anticoagulants vs placebo

Dabigatran (all doses combined) vs placebo · adults after AMI without an indication for anticoagulation

3 findings from 1 review

Non‐vitamin‐K‐antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta‐analysis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1861 participants
Low
Non‐vitamin‐K‐antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta‐analysis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1861 participants
Low
Non‐vitamin‐K‐antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta‐analysis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1861 participants
Low

Intervention not reported

APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 4930 participants
Moderate

Intervention not reported

RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1546 participants
Very low

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1399 participants
Low

Intervention not reported

DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1962 participants
Low

Intervention not reported

DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1527 participants
Low

Intervention not reported

APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 4865 participants
Moderate

Intervention not reported

RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1546 participants
Very low

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1403 participants
Low

Intervention not reported

DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1962 participants
Moderate

Intervention not reported

DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1527 participants
Low

Intervention not reported

APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 4930 participants
Moderate

Intervention not reported

RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1542 participants
Very low

Intervention not reported

RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1393 participants
Low

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1403 participants
Low

Intervention not reported

DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1962 participants
Low

Intervention not reported

DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1527 participants
Low

Intervention not reported

APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 4614 participants
Moderate